Antidepressants Not Working: Treatment-Resistant Depression Workup

"Taking the antidepressant for 6 weeks, no effect" is a common clinical situation. Most patients and clinicians at this point think about switching. But between prescription and result there are often biochemical factors blocking the antidepressant from working: inflammation, neurotransmitter cofactor deficiency, individual CYP450 metabolism. They can be tested — and often this changes the plan more than switching the drug.

Why Antidepressants Don't Work: The Statistics

Per large studies (STAR*D and similar), only 30–40% of patients respond adequately to the first SSRI. Another 20–30% partially respond but don't achieve remission. The remaining 30–40% are resistant, and their treatment requires combinations, augmentation, or class change.

This isn't "bad drugs" — it's real neurobiological heterogeneity of depression and anxiety. Under one diagnosis hide different biological subtypes:

• Serotonergic (classic SSRI response)
• Dopamine-noradrenergic (better with SNRIs and bupropion)
• Inflammatory (poor SSRI response, requires anti-inflammatory strategy)
• Deficiency-driven (folate/B12/vitD/iron deficits)
• With genetic fast/slow drug metabolism

Biochemical causes of resistance are often correctable — and checking them before a drug switch saves months of fruitless therapy.

Inflammatory Depression: CRP and SSRIs

One of the most important findings of recent years — the link between chronic inflammation and antidepressant resistance. With high-sensitivity C-reactive protein (hs-CRP) > 3 mg/L:

• SSRIs work significantly worse (2010s meta-analyses showed 30–50% efficacy drop)
• Paradoxically, anti-inflammatory strategies (omega-3, celecoxib in trials, gut inflammation control) can improve response
• Inflammation increases IDO enzyme activity, diverting tryptophan from serotonin synthesis into the kynurenine pathway — the biochemical basis of "inflammatory depression"

What causes chronic inflammation:

• Visceral obesity (adipose tissue is a pro-inflammatory endocrine organ)
• Chronic infections (Helicobacter, latent viral infections, periodontitis)
• Increased gut permeability ("leaky gut")
• Autoimmune disease
• Smoking
• Chronic sleep deprivation

With hs-CRP > 3 mg/L, it's reasonable to look for the inflammation source in parallel with switching/augmenting the antidepressant.

Neurotransmitter Cofactor Deficiencies

Serotonin, dopamine, noradrenaline, and GABA are synthesized through specific cofactors. Their deficiency is a real and often missed cause of a "non-working" antidepressant.

Folate (folic acid, methylfolate):

Folate is a cofactor for BH4 (tetrahydrobiopterin) synthesis, needed for all monoamines. Low folate produces "biochemical depression" poorly responsive to SSRIs. 30–40% of people have an MTHFR mutation, where ordinary folic acid converts poorly to the active form — requiring methylfolate (L-5-MTHF). SSRI augmentation with methylfolate 7.5–15 mg/day showed effect in several meta-analyses.

Vitamin B12:

Methylation and myelin synthesis cofactor. Low B12 produces brain fog, fatigue, depression. Standard B12 testing misses many — holotranscobalamin (active B12) and methylmalonic acid are more informative.

Vitamin D:

Regulates brain serotonin synthesis. Deficiency < 30 ng/mL is linked to poorer antidepressant response. Target — 40–60 ng/mL.

Magnesium:

GABAergic system activator. Deficiency amplifies the anxious component and worsens SSRI tolerance.

Ferritin:

Low iron reduces dopamine synthesis. Symptoms — apathy, low motivation, fatigue — are part of the depression picture.

All these markers can be checked via the anxiety causes panel.

Metabolism Genetics: CYP2D6 and CYP2C19

Antidepressants are metabolized in the liver by the CYP450 cytochrome system. CYP2D6 and CYP2C19 enzyme activity varies genetically — from "ultra-rapid metabolizers" to "slow."

Consequences:

• Slow metabolizer: drug accumulates in blood → side effects at standard dose → patient stops therapy
• Fast metabolizer: drug clears quickly → effective concentration not reached → "doesn't work" at standard dose

Pharmacogenetic CYP2D6 + CYP2C19 testing is a one-time test in specialized labs. It's meaningful for:

• Resistance to 2+ antidepressants
• Severe side effects at minimal dose
• Family history of antidepressant intolerance

This isn't a routine test — it's indicated for specific clinical scenarios, discussed with a psychiatrist.

Which Tests to Take Before Switching

Minimum "biochemistry of resistance" pack:

1. hs-CRP — inflammatory subtype
2. Vitamin B12 (+ holotranscobalamin if suspected)
3. Folate (preferably red-cell) — monoamine synthesis cofactor
4. Vitamin D 25-OH — serotonergic regulation
5. Magnesium (preferably red-cell)
6. Ferritin — dopamine synthesis
7. TSH + free T4 — thyroid function affects antidepressant response
8. Cortisol morning — hypercortisolism reduces SSRI effect
9. Fasting glucose + insulin — metabolic status
10. Homocysteine — methylation marker

Conveniently in one comprehensive anxiety causes panel. With indication, add CYP2D6/CYP2C19 test through a psychiatrist.

When to See a Psychiatrist

The decision to switch or augment antidepressant therapy is the psychiatrist's. Lab findings are tools for the clinical conversation, not grounds for self-discontinuation.

Urgent psychiatric consultation — for:

• Worsening depressive-anxious symptoms on therapy
• New or intensified suicidal thoughts
• Psychotic symptoms
• Manic switch (possibility in bipolar spectrum)

Scheduled discussion — for:

• No effect after 6–8 weeks of adequate therapy
• Partial response with residual symptoms
• Severe side effects at minimal dose
• Biochemical findings (high CRP, deficiencies) that may affect response

For the broader approach see anxiety: which lab tests and anxiety pills: which lab tests.

This article is for informational purposes only and does not replace professional medical advice. Antidepressant changes are coordinated with a psychiatrist.